Opiant Pharmaceuticals Inc (NASDAQ:OPNT) CEO Roger Crystal sold 28,773 shares of the stock in a transaction on Monday, April 8th. The shares were sold at an average price of $12.03, for a total transaction of $346,139.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Roger Crystal also recently made the following trade(s):

  • On Thursday, April 4th, Roger Crystal sold 21,227 shares of Opiant Pharmaceuticals stock. The stock was sold at an average price of $12.00, for a total transaction of $254,724.00.
  • On Tuesday, January 8th, Roger Crystal sold 50,000 shares of Opiant Pharmaceuticals stock. The shares were sold at an average price of $13.34, for a total transaction of $667,000.00.

NASDAQ OPNT opened at $12.03 on Wednesday. Opiant Pharmaceuticals Inc has a 1-year low of $11.52 and a 1-year high of $29.55. The company has a market cap of $47.36 million, a price-to-earnings ratio of -1.69 and a beta of 0.53.

Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its earnings results on Thursday, March 21st. The technology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.29). The company had revenue of $4.76 million during the quarter, compared to analyst estimates of $5.20 million. Opiant Pharmaceuticals had a negative return on equity of 93.00% and a negative net margin of 93.66%. Equities research analysts predict that Opiant Pharmaceuticals Inc will post -0.38 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the stock. Advisor Group Inc. grew its position in Opiant Pharmaceuticals by 57.2% in the fourth quarter. Advisor Group Inc. now owns 4,700 shares of the technology company’s stock valued at $69,000 after acquiring an additional 1,710 shares during the period. BlackRock Inc. lifted its holdings in shares of Opiant Pharmaceuticals by 44.0% during the fourth quarter. BlackRock Inc. now owns 10,259 shares of the technology company’s stock valued at $149,000 after acquiring an additional 3,137 shares during the period. Eversept Partners LP bought a new position in shares of Opiant Pharmaceuticals during the fourth quarter valued at $201,000. Brasada Capital Management LP boosted its stake in shares of Opiant Pharmaceuticals by 36.0% in the 4th quarter. Brasada Capital Management LP now owns 20,400 shares of the technology company’s stock valued at $295,000 after purchasing an additional 5,400 shares in the last quarter. Finally, Northern Trust Corp acquired a new stake in shares of Opiant Pharmaceuticals in the 2nd quarter valued at $350,000. 19.58% of the stock is currently owned by institutional investors and hedge funds.

Separately, ValuEngine raised shares of Opiant Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, April 1st.

TRADEMARK VIOLATION WARNING: “Insider Selling: Opiant Pharmaceuticals Inc (OPNT) CEO Sells 28,773 Shares of Stock” was originally posted by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/insider-selling-opiant-pharmaceuticals-inc-opnt-ceo-sells-28773-shares-of-stock/2952022.html.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Featured Story: Back-End Load

Insider Buying and Selling by Quarter for Opiant Pharmaceuticals (NASDAQ:OPNT)

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.